Rituximab‐associated infusion reactions (IRs) are significant burdens on oncology patients, caregivers and healthcare providers. We evaluated whether montelukast and rupatadine improve rituximab delivery, decrease frequency/severity of IRs and the number of medications used to control IRs. Using a nonrandomized clinical study design, we assessed adult rituximab naïve patients with B‐cell lymphoid malignancies from January 2017 to July 2019. Prior to the first rituximab infusion patients received one of the premedication regimens: (i ) standard premedications, diphenhydramine hydrochloride and acetaminophen (“SP” group); (ii ) SP + montelukast (“M” group); (iii ) SP + rupatadine (“R” group); (iv ) SP + rupatadine + montelukast Schedule 1 (“M + R Schedule 1” group); (v ) SP + rupatadine + montelukast Schedule 2 (“M + R Schedule 2” group). A total of 223 patients with a median age of 69 years were assessed. Demographics and treatment groups were comparable among all five groups. Mean rituximab infusion time was 290 min in the SP group versus 273, 261, 243 and 236 min in the M, R, M + R Schedule 1 and M + R Schedule 2 groups, respectively. The incidence of rituximab IRs was 75% in the SP group versus 44, 41, 22 and 22% in the M, R, M + R Schedule 1 and M + R Schedule 2 groups, respectively. The median reaction grade was 2 in the SP group and 0 in all other groups. The median number of rescue medications was 3 in the SP group and 0 in all other groups. In conclusion, montelukast and rupatadine significantly improved rituximab delivery, decreased the rate and severity of IRs and reduced the need for rescue medications.

中文翻译：

---

孟鲁司特和卢帕他定的联合用药减少了利妥昔单抗的输注时间，速率，反应的严重程度和急救药物的使用。

利妥昔单抗相关的输注反应（IR）是肿瘤患者，护理人员和医疗保健提供者的沉重负担。我们评估了孟鲁司特和卢帕他定是否改善了利妥昔单抗的输送，降低了IR的频率/严重性以及用于控制IR的药物数量。使用非随机临床研究设计，我们评估了从2017年1月至2019年7月患有B细胞淋巴恶性肿瘤的利妥昔单抗成人患者。在首次利妥昔单抗输注之前，患者接受了以下一种预治疗方案：（i）标准药物，盐酸苯海拉明和对乙酰氨基酚（“ SP”组）；（ii）SP +孟鲁司特（“ M”组）；（iii）SP +鲁帕他定（“ R”组）；（四）SP +鲁帕他定+孟鲁司特附表1（“ M + R附表1”组）；（v）SP +鲁帕他定+孟鲁司特附表2（“ M + R附表2”组）。评估了223名中位年龄为69岁的患者。在所有五个组中，人口统计学和治疗组具有可比性。SP组的平均利妥昔单抗输注时间为290分钟，而M，R，M + R附表1和M + R附表2组的平均输注时间分别为273、261、243和236分钟。利妥昔单抗的IR的发生率为75％的SP组与M，R，M + R附表1和M + R附表2组分别为44％，41％，22％和22％。SP组中位反应等级为2，其他所有组为0。SP组中，急救药物的中位数为3个，其他所有组为0个。总之，孟鲁司特和卢帕他定显着改善了利妥昔单抗的递送，降低了IR的发生率和严重程度，并减少了急救药物的需求。